Elanco Animal Health Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone Q4 report. Elanco operates as a single-segment global animal-health company, selling pet and farm-animal products in more than 90 countries.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | 2023 | 2022 |
|---|---|---|
| Revenue | $4,417 | $4,411 |
| Cost of sales (% of revenue) | $1,931 (44%) | $1,913 (43%) |
| Implied gross margin | Approximately 56% | Approximately 57% |
| R&D expense | $327 | $321 |
| Marketing, selling and administrative expense | $1,285 | $1,265 |
| Goodwill impairment | $1,042 | — |
| Loss before income taxes | $(1,195) | $(72) |
| Net loss | $(1,231) | $(78) |
| Loss per diluted share | $(2.50) | $(0.16) |
| Cash from operating activities | $271 | $452 |
- Pet Health revenue was $2,104 million, down 2% reported and 1% at constant currency. Farm Animal revenue was $2,271 million, up 2% reported and 4% at constant currency. Pricing contributed 4% to total revenue growth, offset by foreign exchange and volume effects.
- Operating cash flow declined $181 million, primarily because interest-rate swap settlement proceeds were $150 million lower year over year; higher inventory also used cash. Capital expenditures were $140 million.
- At year-end, cash and cash equivalents were $352 million; current assets were $3,407 million and current liabilities were $1,241 million. Debt was $5,774 million, including $38 million current and $5,736 million long-term. The company reported compliance with debt covenants.
- Inventory rose to $1,735 million from $1,538 million. Interest expense increased to $277 million from $241 million; cash interest paid was $379 million. Approximately 78% of long-term debt bore a fixed rate, including the effect of swaps.
Material changes versus 2022
- Revenue was essentially flat. Pet Health weakness reflected lower retail parasiticide demand in Spain and competitive pressure in the U.S. veterinary channel; Farm Animal growth was driven mainly by pricing and poultry strength.
- Net loss widened substantially, principally due to the $1,042 million non-cash goodwill impairment recorded after higher long-term Treasury rates increased the discount rate used in the valuation. No additional goodwill impairment was recorded in Q4.
- Cost of sales rose faster than revenue, with the reported cost-of-sales ratio increasing to 44% from 43%. Management cited inflation and reduced manufacturing throughput as it worked to reduce inventory.
- Other expense increased to $75 million from $32 million, including foreign-currency losses of $50 million, a $15 million Seresto litigation provision and a $12.5 million SEC-related accrual.
Outlook, risks and unusual items
- The company did not provide specific revenue or earnings guidance in the supplied filing text. It expects 2024 capital expenditures of approximately $180–$200 million and says macroeconomic pressures may continue in 2024.
- In February 2024, Elanco agreed to sell its aqua business for approximately $1.3 billion cash, subject to approvals and other closing conditions, with closing anticipated around mid-2024. The business generated $175 million of revenue in each of 2023 and 2022. Elanco intends to use after-tax proceeds to accelerate debt repayment, targeting more than $1 billion of debt paydown. A $55 million termination fee may apply if the transaction fails due to specified regulatory approval issues.
- A February 2024 restructuring is expected to eliminate approximately 420 positions, incur $50–$55 million of 2024 pre-tax charges, and generate $30–$35 million of annualized net savings. Management says the plan shifts international resources toward Pet Health and is expected to reduce foreign-currency exposure, including in Argentina.
- Key exposures include substantial indebtedness and interest costs; future impairment risk; competitive and generic-product pressure; antibiotic-use restrictions; product and supply interruptions; foreign-exchange volatility; and reliance on major products. The top five products/product families represented approximately 31% of 2023 revenue; none individually exceeded 10%.
- Legal matters include a potential Seresto class-action settlement for which $15 million was accrued; the court preliminarily approved the settlement in January 2024, with final approval hearing scheduled for December 2024. Elanco accrued $12.5 million for a possible SEC resolution concerning historical channel inventory and sales practices; resolution and terms remain uncertain. Other shareholder and competition litigation is ongoing.
- The EPA completed its review of Seresto in July 2023 and confirmed continued registration. The company also reported that its 2022 material weakness relating to review of the annual tax provision was remediated in 2023; the auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Whether and when the aqua-business sale closes, the after-tax proceeds received, and the actual debt repayment achieved.
- Whether operating cash flow improves as inventory is reduced, and whether inventory levels or distribution-channel stocks create further revenue or cash-flow volatility.
- Whether the goodwill valuation assumptions remain supportable and whether further impairment charges are recorded.
- Progress and realized savings from the restructuring, including its costs, execution, and impact on growth and customer coverage.
- Resolution and final cost of the SEC matter and Seresto settlement, plus outcomes of other material litigation.
- Debt maturities, borrowing costs, covenant headroom, and the company’s ability to service debt while funding operations and investment.